How does the World Health Organization decide guidelines on obesity drugs for children?

Numbers match the citations in the article. A working link isn't proof that a page supports a claim; check the quoted passage and date.

1. 1

   New global guidelines warn against obesity drugs for children under 10

   BBC NewsPublished Oct 7, 2026Checked Oct 13, 2026

   “Care should focus on healthy eating and exercise, not medicines such as weight-loss injections, says the World Health Organization”

2. 2

   Pharmacotherapy for Children and Adolescents With Overweight or Obesity: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.

   Diabetes, obesity & metabolism (Luo et al.)Published Jun 17, 2026Checked Oct 13, 2026

   “A frequentist network meta-analysis was performed using a random-effects model. We used the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach to evaluate the overall certainty of evidence and categorized the interventions.ResultsA total of 41 RCTs (N = 3923) were included. Compared with lifestyle modification alone, semaglutide produced the largest reduction in the 95th BMI percentile (MD -20.40%, 95% CI -24.22 to -16.58), with an additional 500 and 399 patients per 1000 person-years achieving ≥ 5% and ≥ 10% BMI reduction, respectively. Phentermine-topiramate showed the next largest reduction (MD -18.35%, 95% CI -22.26 to -14.45), corresponding to 554 and 734 additional responders per 1000 person-years. Liraglutide and exenatide also significantly reduced the 95th BMI percentile compared with lifestyle modification alone, although the reductions were smaller than those achieved with semaglutide and phentermine-topiramate.ConclusionsBoth semaglutide and phentermine-topiramate were closely linked to weight management, and phentermine-topiramate, with its favourable tolerability, may serve as the optimal adjunct to lifestyle interventions.”

3. 3

   Current and forthcoming pharmacotherapies for adolescent obesity: Evidence-based review.

   World journal of clinical pediatrics (Fuentes-Mendoza et al.)Published Sep 9, 2026Checked Oct 13, 2026

   “Therefore, this minireview aims to compare and clarify the effectiveness of treatments. It also seeks to identify areas requiring attention to guide clinical practice and future research. A literature search was conducted in databases including PubMed and Scopus. The study focused on randomised trials and meta-analyses in patients aged 12 to 18 years and lasting more than 12 weeks. The results show an improvement induced by glucagon-like peptide 1 receptor agonists, such as semaglutide. Semaglutide reduces body mass index by 16.1%. It is more effective than liraglutide in improving insulin sensitivity. The use of these drugs faces challenges, such as cost. There are also social inequalities that affect health equity. Although no short-term safety issues have been reported, there is still little information available on Tirzepatide and CagriSema in adolescents, compared to their known effect on adults. Therefore, we conclude that semaglutide is the current gold standard, but that there is an urgent need for longer-term studies, comparative evaluations, and safety trials that include paediatric cohorts in order to ensure safe access to pharmacological innovations.”

4. 4

   Prevalence and Predictors of Guideline Concordant Pediatric Obesity Care: A Narrative Review.

   Current obesity reports (Orr et al.)Published Apr 14, 2026Checked Oct 13, 2026

   “Screening for comorbidities such as dyslipidemia, diabetes, and metabolic dysfunction-associated steatoic liver disease (MASLD) remains low despite longstanding recommendations. Treatment-related KASs (11–13) show significant gaps: referrals to intensive health behavior and lifestyle interventions are infrequent, pharmacotherapy use is < 2% among eligible adolescents, and bariatric surgery referrals remain rare. Barriers include provider hesitancy, resource limitations, and systemic inequities; facilitators include electronic health record integration, multidisciplinary teams, and expanded insurance coverage. Despite strong evidence supporting early and intensive treatment of pediatric obesity, guideline adoption remains inconsistent. Addressing structural barriers, improving provider education, and leveraging health system innovations are critical for implementation. Future research should evaluate effective implementation strategies, long-term outcomes of pharmacotherapy, and approaches to adapt guidelines to local contexts.”

5. 5

   Specialty-based variation in glucagon-like Peptide-1 receptor agonist prescribing practices for adolescent obesity in Saudi Arabia.

   Obesity pillars (Kalagi et al.)Published Sep 2, 2026Checked Oct 13, 2026

   “The survey assessed prescribing practices, clinical perspectives, perceived barriers, and educational needs related to the use of GLP-1 receptor agonists for adolescent obesity. Comparisons across healthcare specialties were performed using chi-square and Fisher's exact tests, and reflexive thematic analysis was applied to responses to an optional open-ended question.ResultsA total of 140 healthcare professionals completed the survey, of whom 30% reported prescribing GLP-1 RAs for adolescent obesity. Pharmacological treatment was reported more frequently by endocrinologists and bariatric surgeons than by family medicine physicians, general pediatricians, and clinical nutritionists (p ConclusionsConsiderable specialty-based variation exists in GLP-1 RA prescribing practices for adolescent obesity in Saudi Arabia. These findings support the development of standardized national guidance, targeted professional education, and multidisciplinary care pathways to promote consistent, safe, and evidence-based prescribing.”